Wave Life Sciences Ltd. , a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.
Wave Life Sciences stock last closed at $7.10, up 0.14% from the previous day, and has increased 22.41% in one year. It has overperformed other stocks in the Biotechnology industry by 0.41 percentage points. Wave Life Sciences stock is currently +41.43% from its 52-week low of $5.02, and -67.33% from its 52-week high of $21.73.
At the moment, there are 188.25M shares of WVE outstanding. The market capitalization of WVE is $1.34B. In the last 24 hours, 2.67M WVE shares were traded.
You need an online brokerage account to access the NASDAQ market and buy WVE shares.
In our opinion, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen your brokerage, you need to fill out some personal information so you are able to invest in WVE today.
Now that you have opened your account on the best stock app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring money into your investment account.
After you have identified the best place to buy Wave Life Sciences stock, it's absolutely critical to analyze their stock prior to investing, so you truly understand the risk and upside.
WallStreetZen was built to help part-time investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on WVE's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge WVE's fair value.
Using relative valuations methods:
You can access more valuation analysis on WVE's stock here.
Out of 13 Equities analysts who give forecasts on WVE, the consensus analyst rating on Wave Life Sciences is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Andrew S. Fein, a top 14% analyst from HC Wainwright & Co. reiterates WVE with a buy rating and maintains their WVE price target from $30.00 to $30.00, on Mar 2, 2026.
Steve Seedhouse, a top 26% analyst from Cantor Fitzgerald maintains WVE with a strong buy rating and raises their WVE price target from $34.00 to $41.00, on Feb 5, 2026.
Cheng Li, a bottom 19% analyst from Oppenheimer maintains WVE with a buy rating and raises their WVE price target from $24.00 to $32.00, on Dec 16, 2025.
Joon Lee, a top 2% analyst from Truist Securities maintains WVE with a strong buy rating and raises their WVE price target from $36.00 to $50.00, on Dec 15, 2025.
Truist Securities's Joon Lee raised their price target on Wave Life Sciences (NASDAQ: WVE) by 38.9% from $36 to $50 on 2025/12/15. The analyst maintained their Strong Buy rating on the stock.
Lee contextualized their price target by pointing out that Truist Securities' obesity model for WVE-007 is a "conservative placeholder" because it tracks maturing data that may fundamentally shift the conversation from "weight loss" to "quality weight loss" that, if successfully developed, could drive greater utilization of WVE-007 at a higher premium.
Their firm expects competition for WVE-007, the analyst noted, but also sees Wave Life Sciences' stereopure siRNA platform with innovative backbone chemistry as offering a wide moat that four consecutive successful data readouts have now validated.
Madison El-Saadi, a top 27% analyst from B. Riley Securities maintains WVE with a strong buy rating and raises their WVE price target from $19.00 to $37.00, on Dec 12, 2025.
You can dig deeper into what analysts are saying on the Wave Life Sciences stock forecast page.
Last year, WVE revenue was $42.73M. During the last five year, WVE's revenue has increased by 16.31% per year. This was slower than the Biotechnology industry average of 28%.
Dive into WVE's earnings and revenue performance here.
Over the past year, executives and large shareholders at WVE have bought more shares than they have sold.
Ra Capital Management LP, Director of WVE, was the latest WVE insider to buy. They bought $6,312,091.50 worth of WVE shares on Mar 30, 2026.
Learn more about who owns WVE stock here.
No, Wave Life Sciences doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
You have two main options:
Press the Open button and your broker will place your order.
If you want additional help buying stocks on eToro, click the how to video below:
Now that you own some WVE stock, you'll want to keep up with your new investment.
Make a watchlist to keep tabs on your WVE stock.
To reiterate, here are the 6 steps for buying Wave Life Sciences stock:
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Wave Life Sciences, get started below.